Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 7:55 PM
Ignite Modification Date:
2025-12-24 @ 7:55 PM
NCT ID:
NCT01638104
Brief Summary:
The purpose of this study was to investigate the safety and tolerability of ANX-042 when administered by continuous intravenous (IV) infusion in healthy volunteers.
Detailed Description:
Each participant received a total of two, approximately 12-hour continuous infusions of ANX-042 and one 12-hour continuous infusion of placebo, with a 36-hour washout period between treatments.
This study was conducted by Anexon, Inc. at Celerion, in Lincoln, Nebraska.
Study:
NCT01638104
Study Brief:
Protocol Section:
NCT01638104